Barclays upgraded Alignment Healthcare (ALHC) to Equal Weight from Underweight with a price target of $13, up from $9. The company’s solid Q2 report reduces the downside risk to earnings estimates this year, the analyst tells investors in a research note. However, the firm believes the stock’s valuation remains rich, limiting the upside side.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALHC:
- Alignment Healthcare upgraded to Equal Weight from Underweight at Barclays
- Alignment Healthcare Reports Strong Q2 2025 Results
- Closing Bell Movers: Microsoft jumps 9%, Meta up 12% on earnings beats
- Alignment Healthcare reports Q2 diluted EPS 7c, consensus (1c)
- Alignment Healthcare sees Q3 revenue $970M-$985M, consensus $956.8M